ExodusPoint Capital Management LP Sells 417,051 Shares of Illumina, Inc. (NASDAQ:ILMN)

ExodusPoint Capital Management LP lowered its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 94.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,873 shares of the life sciences company's stock after selling 417,051 shares during the quarter. ExodusPoint Capital Management LP's holdings in Illumina were worth $3,057,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ILMN. Golden State Wealth Management LLC bought a new stake in shares of Illumina in the 4th quarter valued at approximately $32,000. Versant Capital Management Inc boosted its stake in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina in the fourth quarter valued at $45,000. Assetmark Inc. raised its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina during the fourth quarter valued at $48,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Analysts Set New Price Targets

ILMN has been the topic of several analyst reports. Robert W. Baird lowered their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Citigroup decreased their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Canaccord Genuity Group cut their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Royal Bank of Canada decreased their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday. Finally, Stephens reaffirmed an "overweight" rating and set a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $138.70.

Remove Ads

Illumina Trading Up 4.9 %

ILMN traded up $3.52 during trading on Friday, reaching $74.78. 3,040,860 shares of the company's stock were exchanged, compared to its average volume of 2,265,473. The company's fifty day moving average price is $88.58 and its 200-day moving average price is $122.32. The firm has a market capitalization of $11.85 billion, a PE ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.